Trial Profile
Efficacy and safety of infliximab biosimilar Inflectra in patients with severe refractory sarcoidosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Mar 2018
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Sarcoidosis
- Focus Adverse reactions; Therapeutic Use
- 19 Feb 2018 Results (n=35) published in the Respiratory Medicine.
- 13 Jul 2017 New trial record
- 24 May 2017 Results (n=27) presented at the 113th International Conference of the American Thoracic Society